Research Article
Year 2023,
Volume: 24 Issue: 4, 349 - 356, 30.12.2023
Abstract
References
- 1. Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49: 2-19.
- 2. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 2022; 80: 920-43.
- 3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra Bet al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009; 35: 119-30.
- 4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014; 72: 1938-56.
- 5. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011; 142: 1243-51.
- 6. Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg 2015; 73: 1095-105.
- 7. El Osta L, El Osta B, Lakiss S, Hennequin M, El Osta N. Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians. Support Care Cancer 2015; 23: 2825-31.
- 8. Ahmadov R, Karacaoğlu F, Akkaya M. Knowledge, opinions and behaviors of dentists regarding bisphosphonates and bisphosphonate-related osteonecrosis of jaw. Turkiye Klinikleri J Dental Sci 2018; 24: 114-22.
- 9. López-Jornet P, Camacho-Alonso F, Molina-Miñano F, GomezGarcia F. Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. J Eval Clin Pract 2010; 16: 878-82.
- 10. Hajmohammadi E, Sattarzadeh S, Amani F. Knowledge rate of dentists regarding dental consideration of bisphosphonate drug user patients. J Res Med Den Sci 2015; 3: 194-8.
- 11. de Lima PB, Brasil VL, de Castro JF, de Moraes Ramos-Perez FM, Alves FA, dos Anjos Pontual ML, et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonaterelated osteonecrosis of the jaw. Support Care Cancer 2015; 23: 3421-6.
- 12. Escobedo MF, García-Consuegra L, Gay S, Álvarez L, Olay S, Ascani G, et al. Influence of the teaching program on the learning in knowledge and practice of osteonecrosis of the jaws produced by antireasorptives in dental students of the Principality of Asturias (Spain). J Clin Exp Dent 2017; 9: e1402-7.
- 13. Gaballah K, Hassan M. Knowledge and attitude of dentists on bisphosphonates use in the UAE: a descriptive cross-sectional study. Int Surg 2017; 4: 1398-404.
- 14. AAOM clinical practice statement: Subject: The use of serum C-terminal telopeptide cross-link of type 1 collagen (CTX) testing in predicting risk of osteonecrosis of the jaw (ONJ). Oral Surg Oral Med Oral Pathol Oral Radiol 2017; 124: 367-8.
- 15. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7.
- 16. Yoo JY, Park YD, Kwon YD, Kim DY, Ohe JY. Survey of Korean dentists on the awareness on bisphosphonate-related osteonecrosis of the jaws. J Investig Clin Dent 2010; 1: 90-5.
- 17. Hristamyan-Cilev MA, Pechalova PP, Raycheva RD, Hristamyan VP, Kevorkyan AK, Stoilova YD. Bisphosphonate-associated Osteonecrosis of the Jaws: a Survey of the Level of Knowledge of Dentists about the Risks of Bisphosphonate Therapy. Folia Med (Plovdiv) 2019; 61: 303-11.
- 18. Arnaud MP, Talibi S, Lejeune-Cairon S. Knowledge and attitudes of French dentists on bone resorption inhibitors (bisphosphonates and denosumab): A cross-sectional study. J Stomatol Oral Maxillofac Surg 2022; 123: 163-70.
- 19. Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health. 2016; 16: 92.
- 20. Miranda-Silva W, Montezuma MA, Benites BM, Bruno JS, Fonseca FP, Fregnani ER. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals. Support Care Cancer 2020; 28: 5397-404.
- 21. Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians' awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J 2011;32:830-5.
Awareness of Oral and Medical Healthcare Professionals in the Prevention, Diagnosis, and Management of Bisphosphonate-related Osteonecrosis of the Jaw
Abstract
Objective: The aim of this study was to evaluate the awareness and knowledge of oral and medical healthcare professionals regarding the prevention, diagnosis, and management of bisphosphonate-related osteonecrosis of the jaw (BRONJ).
Materials and Methods: Two surveys were conducted with oral and medical healthcare professionals to evaluate their knowledge and attitude about bisphosphonates and their experiences with BRONJ.
Results: A total of 385 oral and 119 medical healthcare responses were obtained. The level of knowledge of oral healthcare professionals who practiced for less than 10 years was significantly higher than that of those practicing for more than 10 years (p<0.05). Oral surgeons and periodontists had the highest level of knowledge (p<0.05). The knowledge level scores of the medical healthcare professionals exposed to the necrotic jaw during their careers were significantly higher than those who did not (p<0.05).
Conclusion: Within its limits, the knowledge of medical healthcare professionals was lower than expected. Knowledge of oral healthcare professionals was moderate, except for oral surgeons and periodontists. Multidisciplinary informative platforms between oral and medical healthcare professionals will benefit the management of potential risks and complications related to BPs.
References
- 1. Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49: 2-19.
- 2. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 2022; 80: 920-43.
- 3. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra Bet al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009; 35: 119-30.
- 4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014; 72: 1938-56.
- 5. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2011; 142: 1243-51.
- 6. Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg 2015; 73: 1095-105.
- 7. El Osta L, El Osta B, Lakiss S, Hennequin M, El Osta N. Bisphosphonate-related osteonecrosis of the jaw: awareness and level of knowledge of Lebanese physicians. Support Care Cancer 2015; 23: 2825-31.
- 8. Ahmadov R, Karacaoğlu F, Akkaya M. Knowledge, opinions and behaviors of dentists regarding bisphosphonates and bisphosphonate-related osteonecrosis of jaw. Turkiye Klinikleri J Dental Sci 2018; 24: 114-22.
- 9. López-Jornet P, Camacho-Alonso F, Molina-Miñano F, GomezGarcia F. Bisphosphonate-associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. J Eval Clin Pract 2010; 16: 878-82.
- 10. Hajmohammadi E, Sattarzadeh S, Amani F. Knowledge rate of dentists regarding dental consideration of bisphosphonate drug user patients. J Res Med Den Sci 2015; 3: 194-8.
- 11. de Lima PB, Brasil VL, de Castro JF, de Moraes Ramos-Perez FM, Alves FA, dos Anjos Pontual ML, et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonaterelated osteonecrosis of the jaw. Support Care Cancer 2015; 23: 3421-6.
- 12. Escobedo MF, García-Consuegra L, Gay S, Álvarez L, Olay S, Ascani G, et al. Influence of the teaching program on the learning in knowledge and practice of osteonecrosis of the jaws produced by antireasorptives in dental students of the Principality of Asturias (Spain). J Clin Exp Dent 2017; 9: e1402-7.
- 13. Gaballah K, Hassan M. Knowledge and attitude of dentists on bisphosphonates use in the UAE: a descriptive cross-sectional study. Int Surg 2017; 4: 1398-404.
- 14. AAOM clinical practice statement: Subject: The use of serum C-terminal telopeptide cross-link of type 1 collagen (CTX) testing in predicting risk of osteonecrosis of the jaw (ONJ). Oral Surg Oral Med Oral Pathol Oral Radiol 2017; 124: 367-8.
- 15. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-7.
- 16. Yoo JY, Park YD, Kwon YD, Kim DY, Ohe JY. Survey of Korean dentists on the awareness on bisphosphonate-related osteonecrosis of the jaws. J Investig Clin Dent 2010; 1: 90-5.
- 17. Hristamyan-Cilev MA, Pechalova PP, Raycheva RD, Hristamyan VP, Kevorkyan AK, Stoilova YD. Bisphosphonate-associated Osteonecrosis of the Jaws: a Survey of the Level of Knowledge of Dentists about the Risks of Bisphosphonate Therapy. Folia Med (Plovdiv) 2019; 61: 303-11.
- 18. Arnaud MP, Talibi S, Lejeune-Cairon S. Knowledge and attitudes of French dentists on bone resorption inhibitors (bisphosphonates and denosumab): A cross-sectional study. J Stomatol Oral Maxillofac Surg 2022; 123: 163-70.
- 19. Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health. 2016; 16: 92.
- 20. Miranda-Silva W, Montezuma MA, Benites BM, Bruno JS, Fonseca FP, Fregnani ER. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals. Support Care Cancer 2020; 28: 5397-404.
- 21. Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians' awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J 2011;32:830-5.
There are 21 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Dentistry (Other) |
| Journal Section | Research Article |
| Authors | |
| Publication Date | December 30, 2023 |
| Published in Issue | Year 2023 Volume: 24 Issue: 4 |